留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

影响特发性肺纤维化治疗和预后的常见合并症

李珊 黄慧 徐作军

李珊, 黄慧, 徐作军. 影响特发性肺纤维化治疗和预后的常见合并症[J]. 协和医学杂志, 2018, 9(3): 251-255. doi: 10.3969/j.issn.1674-9081.2018.03.012
引用本文: 李珊, 黄慧, 徐作军. 影响特发性肺纤维化治疗和预后的常见合并症[J]. 协和医学杂志, 2018, 9(3): 251-255. doi: 10.3969/j.issn.1674-9081.2018.03.012
Shan LI, Hui HUANG, Zuo-jun XU. Common Comorbidities in Patients with Idiopathic Pulmonary Fibrosis[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 251-255. doi: 10.3969/j.issn.1674-9081.2018.03.012
Citation: Shan LI, Hui HUANG, Zuo-jun XU. Common Comorbidities in Patients with Idiopathic Pulmonary Fibrosis[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 251-255. doi: 10.3969/j.issn.1674-9081.2018.03.012

影响特发性肺纤维化治疗和预后的常见合并症

doi: 10.3969/j.issn.1674-9081.2018.03.012
基金项目: 

北京市自然科学基金项目 7162157

详细信息
    通讯作者:

    徐作军 电话:010-69155039, E-mail:xuzj@hotmail.com

  • 中图分类号: R563

Common Comorbidities in Patients with Idiopathic Pulmonary Fibrosis

More Information
  • 摘要: 特发性肺纤维化(idiopathic pulmonary fibrosis, IPF)是一种慢性进展性致纤维化性疾病, 预后极差。IPF以中老年男性多见, 容易出现多种临床合并症, 包括肺气肿、肺癌、心血管疾病等。存在合并症的IPF患者临床症状更多、预后更差。本文详细阐述影响特发性肺纤维化治疗和预后的常见合并症, 以期提高临床对于IPF合并症的认识和诊疗水平, 从而改善IPF患者的生活质量及预后。
  • [1] Karampitsakos T, Tzilas V, Tringidou R, et al. Lung cancer in patients with idiopathic pulmonary fibrosis[J]. Pulm Pharmacol Ther, 2017, 45:1-10. doi:  10.1016/j.pupt.2017.03.016
    [2] Tomassetti S, Gurioli C, Ryu JH, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis[J]. Chest, 2015, 147:157-164. doi:  10.1378/chest.14-0359
    [3] Watanabe A, Higami T, Ohori S, et al. Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis?[J].J Thorac Cardiovasc Surg, 2008, 136:1357-1363. doi:  10.1016/j.jtcvs.2008.07.016
    [4] Ono T, Hareyama M, Nakamura T, et al. The clinical results of proton beam therapy in patients with idiopathic pulmonary fibrosis:a single center experience[J].Radiat Oncol, 2016, 11:56. doi:  10.1186/s13014-016-0637-3
    [5] Iwata T, Yoshida S, Nagato K, et al. Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis[J]. Surg Today, 2015, 45:1263-1270. doi:  10.1007/s00595-014-1071-5
    [6] Mediavilla-Varela M, Boateng K, Noyes D, et al. The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts[J].BMC Cancer, 2016, 16:176. doi:  10.1186/s12885-016-2162-z
    [7] Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1):a phase 3, double-blind, randomised controlled trial[J]. Lancet Oncol, 2014, 15:143-155. doi:  10.1016/S1470-2045(13)70586-2
    [8] Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema:a distinct underrecognised entity[J]. Eur Respir J, 2005, 26:586-593. doi:  10.1183/09031936.05.00021005
    [9] Cottin V, Hansell DM, Sverzellati N, et al. Effect of emphysema extent on serial lung function in patients with idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2017, 196:1162-1171. doi:  10.1164/rccm.201612-2492OC
    [10] Sugino K, Ishida F, Kikuchi N, et al. Comparison of clinical characteristics and prognostic factors of combined pulmonary fibrosis and emphysema versus idiopathic pulmonary fibrosis alone[J]. Respirology, 2014, 19:239-245. doi:  10.1111/resp.12207
    [11] Kohashi Y, Arai T, Sugimoto C, et al. Clinical Impact of Emphysema Evaluated by High-Resolution Computed Tomography on Idiopathic Pulmonary Fibrosis Diagnosed by Surgical Lung Biopsy[J]. Respiration, 2016, 92:220-228. doi:  10.1159/000448118
    [12] Mejia M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema:decreased survival associated with severe pulmonary arterial hypertension[J]. Chest, 2009, 136:10-15. doi:  10.1378/chest.08-2306
    [13] Dong F, Zhang Y, Chi F, et al. Clinical efficacy and safety of ICS/LABA in patients with combined idiopathic pulmonary fibrosis and emphysema[J]. Int J Clin Exp Med, 2015, 8:8617-8625. http://europepmc.org/articles/PMC4538025/
    [14] Raghu G, Amatto VC, Behr J, et al. Comorbidities in idiopathic pulmonary fibrosis patients:a systematic literature review[J]. Eur Respir J, 2015, 46:1113-1130. doi:  10.1183/13993003.02316-2014
    [15] Hayes D, Jr., Black SM, Tobias JD, et al. Influence of Pulmonary Hypertension on Patients With Idiopathic Pulmonary Fibrosis Awaiting Lung Transplantation[J]. Ann Thorac Surg, 2016, 101:246-252. doi:  10.1016/j.athoracsur.2015.06.024
    [16] Alkukhun L, Wang XF, Ahmed MK, et al. Non-invasive screening for pulmonary hypertension in idiopathic pulmonary fibrosis[J]. Respir Med, 2016, 117:65-72. doi:  10.1016/j.rmed.2016.06.001
    [17] Idiopathic Pulmonary Fibrosis Clinical Research N, Zisman DA, Schwarz M, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis[J]. N Engl J Med, 2010, 363:620-628. doi:  10.1056/NEJMoa1002110
    [18] Han MK, Bach DS, Hagan PG, et al. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction[J]. Chest, 2013, 143:1699-1708. doi:  10.1378/chest.12-1594
    [19] Mermigkis C, Bouloukaki I, Antoniou K, et al. Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis[J]. Sleep Breath, 2015, 19:385-391. doi:  10.1007/s11325-014-1033-6
    [20] Gille T, Didier M, Boubaya M, et al. Obstructive sleep apnoea and related comorbidities in incident idiopathic pulmonary fibrosis[J]. Eur Respir J, 2017, 49:1601934. doi:  10.1183/13993003.01934-2016
    [21] Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management[J]. Am J Respir Crit Care Med, 2011, 183:788-824. doi:  10.1164/rccm.2009-040GL
    [22] Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis[J]. Eur Respir J, 2006, 27:136-142. doi:  10.1183/09031936.06.00037005
    [23] Lee JS, Song JW, Wolters PJ, et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis[J]. Eur Respir J, 2012, 39:352-358. doi:  10.1183/09031936.00050911
    [24] Lee JS. The Role of Gastroesophageal Reflux and Microaspiration in Idiopathic Pulmonary Fibrosis[J]. Clin Pulm Med, 2014, 21:81-85. doi:  10.1097/CPM.0000000000000031
    [25] Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis:an analysis of data from three randomised controlled trials[J]. Lancet Respir Med, 2013, 1:369-376. doi:  10.1016/S2213-2600(13)70105-X
    [26] Linden PA, Gilbert RJ, Yeap BY, et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation[J]. J Thorac Cardiovasc Surg, 2006, 131:438-446. doi:  10.1016/j.jtcvs.2005.10.014
    [27] Fulton BG, Ryerson CJ. Managing comorbidities in idiopathic pulmonary fibrosis[J]. Int J Gen Med, 2015, 8:309-318. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=Doaj000004008806
    [28] Sprunger DB, Olson AL, Huie TJ, et al. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease[J]. Eur Respir J, 2012, 39:125-132. doi:  10.1183/09031936.00041411
    [29] Dalleywater W, Powell HA, Fogarty AW, et al. Venous thromboembolism in people with idiopathic pulmonary fibr-osis:a population-based study[J]. Eur Respir J, 2014, 44:1714-1715. doi:  10.1183/09031936.00099614
    [30] Nathan SD, Barnett SD, Urban BA, et al. Pulmonary embolism in idiopathic pulmonary fibrosis transplant recipients[J]. Chest, 2003, 123:1758-1763. doi:  10.1378/chest.123.5.1758
    [31] Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2012, 186:88-95. doi:  10.1164/rccm.201202-0314OC
    [32] Rochwerg B, Raghu G. Reply:Can Warfarin Be Used in the Treatment of Pulmonary Embolism in Idiopathic Pulmonary Fibrosis?[J]. Am J Respir Crit Care Med, 2016, 193:811. doi:  10.1164/rccm.201601-0078LE
    [33] Hubbard RB, Smith C, Le JeuneI, et al. The association between idiopathic pulmonary fibrosis and vascular disease:a population-based study[J]. Am J Respir Crit Care Med, 2008, 178:1257-1261. doi:  10.1164/rccm.200805-725OC
    [34] Kim WY, Mok Y, Kim GW, et al. Association between idiopathic pulmonary fibrosis and coronary artery disease:a case-control study and cohort analysis[J]. Sarcoidosis Vasc Diffuse Lung Dis, 2015, 31:289-296. http://www.ncbi.nlm.nih.gov/pubmed/25591140
    [35] Nathan SD, Basavaraj A, Reichner C, et al. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis[J]. Respir Med, 2010, 104:1035-1041. doi:  10.1016/j.rmed.2010.02.008
    [36] Nathan SD, Weir N, Shlobin OA, et al. The value of computed tomography scanning for the detection of coronary artery disease in patients with idiopathic pulmonary fibrosis[J]. Respirology, 2011, 16:481-486. doi:  10.1111/j.1440-1843.2010.01919.x
    [37] Nielsen TD, Bahnson T, Davis RD, et al. Atrial fibrillation after pulmonary transplant[J]. Chest, 2004, 126:496-500. doi:  10.1378/chest.126.2.496
    [38] Gribbin J, Hubbard R, Smith C. Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis[J]. Respir Med, 2009, 103:927-931. doi:  10.1016/j.rmed.2008.11.001
    [39] Enomoto T, Usuki J, Azuma A, et al. Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis[J]. Chest, 2003, 123:2007-2011. doi:  10.1378/chest.123.6.2007
    [40] Kim YJ, Park JW, Kyung SY, et al. Clinical characteristics of idiopathic pulmonary fibrosis patients with diabetes mellitus:the national survey in Korea from 2003 to 2007[J]. J Korean Med Sci, 2012, 27:756-760. doi:  10.3346/jkms.2012.27.7.756
  • 加载中
计量
  • 文章访问数:  209
  • HTML全文浏览量:  8
  • PDF下载量:  341
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-12-18
  • 刊出日期:  2018-05-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!